ArticleJournal of ovarian research2026
Prevalence of ovarian cancer cachexia in patients undergoing cytoreductive surgery at the University of Colorado between 2014-2024.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCancer cachexia is an underrecognized condition characterized by weight loss and muscle wasting resulting from altered metabolism and systemic inflammation. While this comorbid condition is associated with surgical complications and poorer prognosis in other cancer types, its prevalence in epithelial ovarian cancer is not well described. We evaluated the prevalence of cachexia in patients with epithelial ovarian cancer and clinical characteristics associated with cachexia.
methodsA retrospective cohort study with longitudinal follow up was performed on 374 patients who underwent cytoreductive surgery for epithelial ovarian cancer. Adult patients, without risk factors for sarcopenia, who underwent surgery from January 2014-June 2024 were evaluated for preoperative weight, skeletal muscle index, demographics, physical and tumor characteristics, oncologic treatment, and outcomes with cancer cachexia.
resultsCancer cachexia was common (> 50% of cohort) and more frequently observed in patients who had interval cytoreductive surgery (odds ratio [OR] 3.34, 95% CI 2.16–5.06), required preoperative paracentesis or thoracentesis (OR 4.45, 95% CI 2.73–7.28), had advanced-stage disease (OR 3.76, 95% CI 2.17–6.57), serous histology (OR 1.87, 95% CI 1.12–3.11), and aberrant p53 expression (OR 1.77, 95% CI 1.11–2.78). Median Cancer Antigen 125 (CA-125) was higher in the population of patients with cachexia than among those without (p < 0.0001), though discriminatory performance was modest. Cachexia was associated with shorter disease-free survival and overall survival. Median disease-free survival was 19.8 months in patients with cachexia compared with 42.0 months in those without (log-rank p < 0.0001). Median overall survival was 51.2 months versus 72.0 months, respectively (log-rank p = 0.02).
conclusionsOver half of patients with epithelial ovarian cancer will have cachexia at the time of cytoreductive surgery. Risk factors for cachexia include interval cytoreductive surgery, need for paracentesis, advanced stage, serous histology, and aberrant p53 expression. Disease-free survival and overall survival are worse in patients with cachexia compared to those without.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.